Who are Sagimet Biosciences's investors?

Sagimet Biosciences's investors include Altium Capital, HM Venture Partners, Kleiner Perkins, New Enterprise Associates (NEA), BAM Elevate, Biotechnology Value Fund, Blue Owl Capital, Westlake Village BioPartners.

How much funding has Sagimet Biosciences raised?

Sagimet Biosciences has disclosed $123.9M raised across 4 of its 7 known rounds.

Where is Sagimet Biosciences headquartered?

Sagimet Biosciences is headquartered in Menlo Park, US.

Sagimet Biosciences

NASDAQ: SGMT

Menlo Park, US · 15 known investors

Find your way into Sagimet Biosciences

Paths you didn't know you had: your email and LinkedIn already hold routes to the Sagimet Biosciences team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sagimet is a clinical-stage biopharmaceutical company developing therapies targeting fatty acid synthase (FASN) for metabolic diseases and oncology. The company advances drug candidates through clinical trials in areas such as metabolic disease.

Biotech Digital Health Healthtech

Founders & leadership

Rekha Hemrajani Chief Financial Officer, SVP of Business and Financial Operations2015–2016Rekha Hemrajani is an executive leader with background in life sciences strategy, corporate development, finance, and operations, including prior experience in mergers and acquisitions and investment banking.

Merdad ParseyExecutiveExecutive Officer, Director at 3-V Biosciences

David HappelChief Executive Officer & Director

Andreas Grauer Chief Medical OfficerHe is a physician-scientist with over 20 years of pharmaceutical industry experience spanning clinical development, medical affairs, and regulatory strategy across therapeutic areas including endocrinology, oncology, and nephrology, and holds an appointment as Associate Professor of Medicine at the University of Heidelberg Medical School.

Thierry Chauche Chief Financial OfficerThierry Chauche is Chief Financial Officer of Sagimet Biosciences, a clinical-stage biopharmaceutical company developing therapies for metabolic diseases and oncology. He brings experience in biopharma corporate finance, M&A transactions, and investor relations.

Marie O'FarrellChief Scientific Officer

Elizabeth RozekChief Legal & Administrative Officer

Board

David MottBoard directorGeneral Partner at New Enterprise Associates

Beth Seidenberg Board directorFounding Managing Director at Westlake Village BioPartners

James YoungBoard director

Robert GarlandBoard director

Richard RodgersBoard director

Investors · 15

Altium Capitallisted by Altium CapitalNew York

How we know: Altium Capital's portfolio page · Not right? Tell us

HM Venture Partnerslisted by HM Venture PartnersSan Francisco

How we know: HM Venture Partners's portfolio page · Not right? Tell us

Kleiner Perkinslisted by Kleiner PerkinsMenlo Park · $500K – $15M

How we know: Kleiner Perkins's portfolio page · board seat on SEC Form D · press coverage · Not right? Tell us

New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40M

How we know: press coverage · Not right? Tell us

BAM ElevatereportedChicago

How we know: allsci.com · Not right? Tell us

Biotechnology Value FundreportedSan Francisco

How we know: allsci.com · Not right? Tell us

Blue Owl CapitalreportedNew York

How we know: briefglance.com · Not right? Tell us

Westlake Village BioPartnersinferredLos Angeles · $100K – $5Mvia Beth Seidenberg · board

How we know: board seat on SEC Form D · Not right? Tell us

Also in the syndicate · 7

BalyasnyBlue Owl Healthcare OpportunitiesCaligan PartnersCoastlands CapitalFarallon Capital ManagementGreat Point PartnersWoodline Partners LP

Funding

SEC filings, press & company announcements

$123.9M disclosed across 4 of 7 rounds · 2014–2026

Undisclosed amountSeries AApr 2026
Balyasny Asset Management, Blue Owl Healthcare Opportunities, BVF Partners L.P., Caligan Partners, Coastlands Capital, Farallon Capital Management, Great Point Partners, Woodline Partners LP
Source ↗

▶$69MraisedJan 2021 · 13 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

George KembleExecutive Officer, Director
Dennis HomExecutive Officer
Merdad ParseyDirector
Beth SeidenbergDirector
Gordon RingoldDirector
Jason FullerDirector
James YoungDirector
Richard RodgersDirector
Jinzi Jason WuDirector

Offering amount: $80M
Amount sold: $69M
First sale: Dec 2020
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$35.2MraisedFeb 2019 · 19 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

George KembleExecutive Officer, Director
Xufang DuanDirector
Jason FullerDirector
Merdad ParseyDirector
David MottDirector
Beth SeidenbergDirector
Richard RodgersDirector
Gordon RingoldDirector
Dennis HomExecutive Officer
Jinzi Jason WuDirector
James YoungDirector

Offering amount: $42.2M
Amount sold: $35.2M
First sale: Feb 2019
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$5.4MraisedJul 2016 · 7 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

James YoungDirector
David MottDirector
Beth SeidenbergDirector
Gordon RingoldDirector
Jason FullerDirector
Merdad ParseyDirector
Richard RodgersDirector
George KembleExecutive Officer, Director

Offering amount: $12M
Amount sold: $5.4M
First sale: Jun 2016
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$14.3MraisedMar 2015 · 12 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

David MottDirector
Rekha HemrajaniExecutive Officer
Beth SeidenbergDirector
Richard RodgersDirector
Gordon RingoldDirector
Merdad ParseyExecutive Officer, Director
James YoungDirector
Robert GarlandDirector

Offering amount: $35M
Amount sold: $14.3M
First sale: Oct 2014
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events

$379.7Mvaluation at IPOJan 2024 · $12.50/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

In the news

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences | The Manila Timesmanilatimes.net · Sep 2026

3-V Biosciences Changes Name to Sagimet Biosciences and Closes $25 Million Financing - Sagimet Biosciencessagimet.com · Aug 2019

3-V Biosciences Announces Closing of $28.5M Financing Round - Sagimet Biosciencessagimet.com · Dec 2014

3-V Biosciences Completes $20 Million Series C Financing - Sagimet Biosciencessagimet.com · Jun 2013

Frequently asked questions

What does Sagimet Biosciences do?: Sagimet is a clinical-stage biopharmaceutical company developing therapies targeting fatty acid synthase (FASN) for metabolic diseases and oncology. The company advances drug candidates through clinical trials in areas such as metabolic disease.
Who are Sagimet Biosciences's investors?: Sagimet Biosciences's investors include Altium Capital, HM Venture Partners, Kleiner Perkins, New Enterprise Associates (NEA), BAM Elevate, Biotechnology Value Fund, Blue Owl Capital, Westlake Village BioPartners.
How much funding has Sagimet Biosciences raised?: Sagimet Biosciences has disclosed $123.9M raised across 4 of its 7 known rounds.
Where is Sagimet Biosciences headquartered?: Sagimet Biosciences is headquartered in Menlo Park, US.